COLBY GROSSMAN: Open Payments
NPI 1619952371 · SUMMERVILLE, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$665 in 47 payments from 15 companies in 2025. Trend: 2023 $847 · 2024 $735 · 2025 $665
Food & beverage: $665
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 23 | $183 |
| Verity Pharmaceuticals Inc. | 4 | $79 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $73 |
| AstraZeneca Pharmaceuticals LP | 3 | $49 |
| TOLMAR, INC. | 2 | $46 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Novartis Pharmaceuticals Corporation | 2 | $34 |
| Dexcom, Inc. | 1 | $33 |
| Edwards Lifesciences Corporation | 1 | $25 |
| Lilly USA, LLC | 1 | $22 |
Products named: OTEZLA, Tlando, JARDIANCE, FARXIGA, JATENZO, LEQVIO, Dexcom G6 Transmitter, SAPIEN 3 Ultra RESILIA.
Industry payments across SC — which companies pay providers there.
